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Objective: To study trends in use of antidepressants (ADs) by
adolescents, and psychiatric morbidity and use of other psychotropic
drugs as a measure of psychiatric comorbidity.
Methods: One-year prevalence of AD drug use was analyzed for 13- to
17-year-old Norwegians during 2004–2013. Use of other psychotropic
drugs and specialist healthcare services was analyzed for incident AD
users in 2012, using linked data from the Norwegian Prescription
Database and the Norwegian Patient Register.
Results: The 1-year prevalence of AD drug use increased from 6.4/1000
to 9.1/1000 during 2004–2013, with the steepest increase from 2010,
particularly among girls. The highest prevalence was found in 17-year-
old girls (17.8/1000 in 2010, 27.5/1000 in 2013). Of incident AD drug
users in 2012, 84.4% had been in contact with specialist health care. As
the ﬁrst drug, 78.4% were prescribed a selective serotonin reuptake
inhibitor. The most common types of other psychotropic drugs were
melatonin (24.6%), antipsychotic drugs (13.2%), stimulants (8.8%),
and anxiolytics (6.0%).
Conclusions: Use of ADs among adolescents has increased over the last
3–4 years, particularly among 16- to 17-year-old girls. A total of 85%
of incident users had been in contact with specialist health care, which
may indicate that drug-therapy is used by adolescents with more severe
symptoms.
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Signiﬁcant outcomes
• Antidepressant (AD) use among adolescents has increased over the last 3–4 years, particularly
among 16- to 17-year-old girls. In 2013, 1.0% of 17-year-old boys and 2.8% of 17-year-old girls were
dispensed an AD.
• Eighty-ﬁve per cent of incident AD users in 2012 had been referred to specialist mental health care,
indicating that AD therapy is started mainly in adolescents with severe symptoms of psychiatric mor-
bidity.
• Eighty per cent of incident users were started on a selective serotonin reuptake inhibitors, which is
recommended for of use in moderate-to-severe depressive illness and anxiety disorders.
Limitations
• We had no information on symptom severity or use of non-pharmacological treatment options in
addition to antidepressants (ADs).
• Data on ADs used while in hospital were not available.
• Prescription data may not necessarily reﬂect actual drug intake because drugs may be dispensed to
individuals but not used.
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Background
In 2004 and 2005, regulatory medical drug agen-
cies in Norway (1), the European Medicines
Agency, and the US Food and Drug Administra-
tion (FDA) raised concerns about the elevated risk
of suicidal thoughts and behaviour in children and
adolescents receiving antidepressants (ADs), lead-
ing to warnings against use of ADs in youths (2,
3). These warnings led to a decline in prescribing
and use of ADs among children and adolescents in
many countries, at least within those with milder
depression (4–6). Since then, it has been an ongo-
ing debate on beneﬁcial vs. harmful eﬀects of ADs
in younger people. A new meta-analysis of avail-
able clinical study reports from randomized clini-
cal trials demonstrated a higher risk of suicidal
ideation and behaviour in children and adolescents
taking ADs (7). Although untreated depressive dis-
order is a strong risk factor for completed suicide,
a recent Cochrane review questions the clinical
eﬀectiveness of ADs (8). Lessons learned from
long-term follow-up studies in community popula-
tions of depressed adolescents emphasize the
importance of combining pharmacological with
non-pharmacological therapy (9). In Norway,
selective serotonin reuptake inhibitors (SSRIs, ﬂu-
oxetine and sertraline in particular) are recom-
mended ﬁrst line if drug-therapy is considered
necessary in moderate-to-severe depression (ﬂuox-
etine) and obsessive–compulsive disorders (OCD;
sertraline) in children and adolescents. Treatment
guidelines for pediatric depression, OCD, and anx-
iety disorders emphasize that drug-therapy should
always be given in combination with psychosocial
interventions and non-pharmacological treatment,
and with a close monitoring of beneﬁcial and
harmful eﬀects (8, 10–12). In recent years, a trend
of increasing use of ADs among children and ado-
lescents has been observed in the USA, Canada,
and European countries (13–18). However, large
diﬀerences in prescribing prevalence of AD drugs
exist between countries, with the highest use of
ADs in the USA (18, 19). This may be explained
partly by cultural factors and diﬀerences in clinical
service delivery (18, 19). In view of the ongoing
debate, and after consideration of the observed rel-
ative increase in prescribing of AD drugs in chil-
dren and adolescents, more detailed information
on use and users is needed.
Aims of the study
The aims of this study were to describe trends in
antidepressant (AD) use among 13- to 17-year-old
Norwegians in terms of prevalence and incidence
of use in the period 2004–2013, and to characterize
incident users in 2012 according to AD drug of
choice, psychiatric morbidity, and use of other psy-
chotropic drugs as a measure of psychiatric comor-
bidity.
Material and methods
Study population
The study population consisted of all individuals
aged 13–17 years in Norway who were dispensed
an AD drug at least once during 2004–2013, as reg-
istered in the Norwegian Prescription Database
(NorPD).
Data sources
The Norwegian Prescription Database. Data on dis-
pensed psychotropic drugs were drawn from the
NorPD, which covers the entire Norwegian popu-
lation (approximately 5.2 million inhabitants)
(20). Since January 2004, all Norwegian pharma-
cies have been obliged to send data electronically
to the Norwegian Institute of Public Health on all
prescribed drugs (irrespective of reimbursement or
not) dispensed to individuals in ambulatory care
(21). Drugs administered to patients while in hos-
pital are not reported to the NorPD. The drugs in
the NorPD are classiﬁed according to the Anatom-
ical Therapeutic Chemical (ATC) classiﬁcation sys-
tem (22). In this study, we included the patients’
unique identity number (encrypted), sex, age, the
date of dispensing, generic drug information (ATC
code), deﬁned daily doses (DDDs), and pre-
scribers’ clinical specialty.
Information was retrieved for the period 2004–
2013 on dispensed drugs classiﬁed as ADs, ATC-
group N06A, tricyclic antidepressants (TCA,
N06AA), SSRIs (N06AB), monoamine inhibitors
(MAO-I, N06AG), and other ADs (N06AX). The
pediatric indications, ATC codes, and DDD deﬁni-
tions for SSRIs licensed for pediatric use are pre-
sented in Table 1. In addition, data on other
dispensed psychotropic drugs were retrieved (ATC
codes in parentheses): antipsychotics (N05A,
excluding lithium, N05AN01), anxiolytics (N05B),
hypnotic and sedatives (N05CD, N05CF,
N05CH), centrally acting sympathomimetics
referred to as stimulants (N06BA), and alimema-
zine (R06AD01). The systemic antihistamine ali-
memazine has long been used for childhood
insomnia in Norway (23), and was therefore
included as a hypnotic/sedative. In the following,
dispensed drugs, as recorded in the NorPD, will be
referred to as ‘used’ drugs.
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The Norwegian Patient Register. The Norwegian
Patient Register (NPR) is an administrative data-
base of records reported by the specialist health
care, that is, all hospitals and out-patient clinics
owned or ﬁnanced by the government. Thus, the
NPR includes information on patients that have
been referred by a general practitioner (GP)
because of a need of specialist health care. All
Norwegian citizens have a dedicated GP who rep-
resents the lowest level of public health care. If a
patient requires treatment at a higher level, the
GP may refer to a specialist healthcare facility,
that is, a hospital, out-patient clinic, or private
practitioner. All referrals and registered contacts
with specialist health care are included in the
NPR. A registered contact in the NPR may thus
indicate a more severe type of illness. In Norway,
government-funded mental health clinics for chil-
dren and adolescents are available throughout the
country, serving the entire population. Mental
health care for children and adolescents is free of
charge. The NPR has included unique personal
identiﬁcation numbers since 2008, and conse-
quently, the register contains nationwide individ-
ual-level specialist healthcare data from 2008 and
onwards (24, 25). In this study, we used data
reported by the specialist health care, hospital-
and out-patient clinics, and substance abuse treat-
ment facilities in the period 2008–2012. Data on
mental and behavioural disorder diagnoses [Inter-
national Classiﬁcation of Diseases, 10th edition
(ICD-10) codes F00-F99] and registered visits in
the specialist child and adolescent mental health
care were obtained for all individuals in the study
population.
Data from the NorPD and the NPR were linked
using the unique personal identity number
assigned to all individuals who are living in
Norway.
Analytical approach
The 1-year prevalence of use of ADs was estimated
by dividing the number of individuals aged 13–
17 years who were dispensed at least one AD drug
within each of the years 2004–2013 by the total
number of inhabitants in Norway in the relevant
age group per 1 July in each year, as registered by
Statistics Norway. For SSRIs, the total amount of
dispensed DDDs was calculated, speciﬁed by type
of SSRI and study year (2004–2013).
Incident users in each of the years 2007–2013
were deﬁned as people having an AD dispensed in
the actual year, and no AD prescriptions during
the 3 years (1095 days) preceding the ﬁrst prescrip-
tion in the actual year. The denominator, the pop-
ulation at risk, was the total number of inhabitants
in Norway in the relevant age group per 1 July in
the actual year, as registered by Statistics Norway,
minus the number of individuals who were preva-
lent users in one of the previous 3 years.
For incident users in 2012, we performed a more
detailed analysis of choice of type of AD at initia-
tion, other types of psychotropic drugs dispensed
in 2012, and referral to specialist mental health ser-
vice during 2008–2012 (registrations in NPR). A
registration in the NPR in terms of a diagnosis of
mental disorders (ICD-10 F00–F99) or any regis-
tered contact with the specialist child and adoles-
cent mental health service was classiﬁed as ‘use of
specialist mental health service’. For further identi-
ﬁcation of contact with other relevant specialist
health care, we used prescriber’s specialty as
recorded in the NorPD to identify treatment by
pediatricians, psychiatrists, and neurologists.
All analyses were performed using SPSS 22.0 for
Windows (IBM Corp., Armonk, NY, USA).
Ethical considerations
The register linkage has been approved by the
Regional Committee for Medical Research Ethics
and by the Norwegian Data Protection Authority.
Results
Trends in 1-year prevalence and incidence in AD use among 13- to
17-year olds
During the years 2004–2013, there was an overall
increase in the 1-year prevalence for use of ADs
from 6.4/1000 to 9.1/1000, but the pattern was not
linear (Fig. 1). After an initial decrease, the total
prevalence increased slightly until it reached the
2004 level in 2010, and then increased markedly
through 2013. The increase in prevalence was
Table 1. SSRIs with marketing authorization in Norway
Drug
ATC
codes
DDD
(mg)
Year
marketed
Pediatric
marketing
Approved indication
in children
Fluoxetine N0AB03 20 1995 2008 Moderate-to-severe
depression
(>7 years of age)
Citalopram N0AB04 20 1995 None
Paroxetine N0AB05 20 1993 None
Sertraline N0AB06 50 1996 2000 Obsessive–compulsive
disorder
(>6 years of age)
Fluvoxamine N0AB08 100 1990 2002 Obsessive–compulsive
disorder
(>8 years of age)
Escitalopram N0AB10 10 2010 None
DDD, defined daily doses; SSRI, selective serotonin reuptake inhibitors.
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particularly strong in girls, from 8.3/1000 in 2010
to 12.4/1000 in 2013. In boys, the prevalence
increased from 5.0/1000 to 5.9/1000 in the same
period. In both genders, the prevalence increased
with age, with the highest proportion of users
observed among 17-year olds in 2013: 10.4/1000 in
boys and 27.5/1000 in girls (Fig. 2).
In general, the prevalence of AD use among the
14- to 17-year olds was higher in girls compared
with boys, and the gender diﬀerences increased
with increasing age: from 2009 to 2013, the relative
increase in use among the 14- to 17-year olds was
57–67% among girls and 17–32% among boys
respectively. The most used SSRIs in the period
Fig. 1. The 1-year prevalence of
antidepressant drug use among 13- to
17-year-old Norwegian adolescents in
the period 2004–2013.
Fig. 2. The 1-year prevalence of
antidepressant use among 13- to 17-
year-old Norwegian adolescents in the
period 2004–2013, according to age and
gender.
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(amount of DDDs) were sertraline followed by ﬂu-
oxetine (Fig. 3).
The incidence was stable until 2009 in girls, and
then, it increased during 2010–2013; for boys, a
weak increase was observed over the whole period
(Fig. 4). The proportion of incident users among
prevalent users was stable throughout the period
(data not shown).
Detailed characteristics of incident AD users in 2012
The great majority (78.4%) of the incident AD
users were started on an SSRI, and ﬂuoxetine
(33.1%), sertraline (27.5%), and escitalopram
(16.0%) were the most prevalent drugs (Table 2).
The TCA amitriptyline was prescribed as the ﬁrst
drug to 8.7% of all new users.
A total of 33.8% of the incident AD users were
also dispensed at least on hypnotic drug in 2012.
The most common was melatonin (used by 24.6%
of the incident users) followed by alimemazine
(11.7%) (Table 3).
A total of 78.7% of the incident users had been
referred to a specialist/hospital by their GP and
were registered in the NPR during 2008–2012 as
users of specialist mental health service, thus a
marker of more severe mental health problems. Of
the remaining, 26.7% had been prescribed ADs by
a psychiatrist, neurologist, or pediatrician. In total,
84.4% of all incident AD users had been in contact
with the specialist healthcare services, and the
remaining 15.6% of incident users were treated by
GPs only.
Discussion
The results of this study demonstrate a marked
increase in ADs use by Norwegian adolescents
during 2010–2013. This pattern was most promi-
nent in girls, for whom a 50% relative increase in
prevalence was observed from 2010 to 2013. The
gender diﬀerence in AD use varied with age and
time, from similar prevalence in girls and boys at
age 13 and 14 throughout the period to almost
three times higher prevalence in girls than in boys
at age 17 in 2013. Among incident AD users in
2012, SSRIs were the ﬁrst drug in about 80%, one-
third was also prescribed a hypnotic drug, and
nearly 85% had been in contact with relevant spe-
cialist healthcare services as a marker of severity of
symptoms.
The development in Norway diﬀers somewhat
from that in Denmark, where a practically linear
ﬁve-fold increase in AD use has been observed
from 2000 to 2011, with a minor drop in 2005
(16). In both Denmark and Norway, the increase
in use of SSRIs over time has been driven by
increased use in adolescents, among girls in par-
ticular (15, 16). Levels of use in boys and girls
were comparable in the two countries. For exam-
ple, around 10/1000 and 20/1000 of all 17-year-
old boys and girls, respectively, had ADs dis-
pensed in 2011. A parallel trend in increasing AD
use among adolescents have been observed in the
USA and other European countries in the period
2005–2012 (18), and in Canada in the period
2005–2009 (14). It is interesting that an opposite
trend has been observed in Iceland, where AD
use decreased from 28.3 to 23.4 per 1000 among
0- to 17-year olds in the period 2003–2007, but
with the strongest decrease from 2004 to 2005
(26). The level of AD use has, however, been con-
sistently higher in Iceland than in the other Nor-
dic countries, for example, in 2007 1.8/1000 of all
boys and 2.6/1000 of all girls aged <18 years were
prescribed ADs in Norway; thus, the level in
Fig. 3. Total use of selective serotonin
reuptake inhibitors (SSRIs), measured
in deﬁned daily doses (DDD) and
speciﬁed by drug substance and year.
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Norway is only about 10% of the level in Iceland
(26, 15).
The increase in AD use among adolescents may
be attributed to several factors. In 2000 and 2009,
the SSRIs sertraline and ﬂuoxetine were approved
for use in children and adolescents in Norway, and
since then, they have been marketed and included
in guidelines for treatment of severe cases of
depressive disorders (ﬂuoxetine) and OCD (sertra-
line). This development paralleled the increase of
AD use among the adolescent population observed
in the present study.
Since warnings were issued by the regulatory
agencies in 2004–2005 (2, 3), new risk–beneﬁt eval-
uations of pediatric use of SSRIs for depression,
OCD, and anxiety disorders have been published.
A recent meta-analysis concludes that use of SSRIs
in children and adolescents doubles the risk of sui-
cidality and aggression (7). When used in pediatric
depressive disorders, a Cochrane review of ran-
domized controlled trials (RCTs) concludes that
while the overall reduction in depressive symptoms
and relapse is statistically signiﬁcant, the eﬀects are
small and there are still questions about the clinical
eﬀectiveness in children and adolescents (8, 27).
Further, because of strict inclusion and exclusion
criteria, patients recruited to RCTs may not be
representative for all patients presenting for treat-
ment. This makes it diﬃcult to draw any ﬁrm con-
clusions. Even though untreated depression is a
strong risk factor for completed suicide and
severely impacts on functioning (8), a careful con-
sideration of potential beneﬁts and risk should pre-
cede initiation of AD drug-therapy in children and
adolescents. AD prescriptions should always be
combined with non-pharmacological treatment
options, and close follow-up and monitoring of
eﬀects and side-eﬀects (8, 11).
In pediatric OCD, both international and
national guidelines (10, 12) recommend cognitive
behaviour therapy (CBT) as a ﬁrst-line treatment,
with SSRIs (sertraline is licensed and thus recom-
mended as ﬁrst choice) being an endorsed treat-
ment option where CBT fails or in severe cases (10,
12, 28). Currently published evidence suggests that
SSRIs are eﬀective in treating children and young
people with severe OCD (28). It is not known
whether the same risk of suicidality occurs with
0
2
4
6
8
10
12
14
16
13 14 15 16 17 Total
In
ci
de
nc
e 
(n
ew
 u
se
rs
 p
er
 1
00
0)
Age (years)
Boys
2007
2008
2009
2010
2011
2012
2013
0
2
4
6
8
10
12
14
16
13 14 15 16 17 Total
In
ci
de
nc
e 
(n
ew
 u
se
rs
 p
er
 1
00
0)
Age (years)
Girls
2007
2008
2009
2010
2011
2012
2013
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antidepressant (AD) use in 13- to 17-
year olds in the period 2007–2013 in
Norway, according to age and gender.
1Incident use was deﬁned as no ADs
dispensed during the 3-year period
before the ﬁrst dispensing in the actual
year.
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their use in OCD, but similar adverse reactions
cannot be ruled out, and appropriate caution
should be observed, especially in the presence of
comorbid depression (10, 12).
In Norway, use of SSRIs is approved for use in
children and adolescents with moderate/severe
depressive illness or OCD, but not anxiety
disorders (10). However, in severe cases, an SSRI
(sertraline ﬁrst choice) may be initiated, always in
combination with psychosocial interventions. Evi-
dence supports the eﬃcacy of newer ADs in
treating pediatric anxiety disorders, but with a
moderate eﬀect size (29).
So, does the observed increase in AD drug use
reﬂect increasing prevalence of indications for their
use: moderate/severe depression, anxiety, and
OCD? Self-reported mental distress has increased
among adolescents in Norway: about 15% of 15-
to 16-year olds in one county in Norway reported
mental distress in 2001, increasing to 25% in 2009
(30). Still, we do not know whether there has been
an increase in severity of depression, OCD, and
anxiety in the adolescent population in Norway
over time, corresponding to the observed increase
in AD use. A recent meta-analysis of studies using
standardized diagnostic interviews for DSM-IV
disorders among children and adolescents revealed
prevalence estimates of any anxiety disorder and
any depressive disorder at 6.5% and 2.6% respec-
tively (31). In the interview-based National
Comorbidity Survey Replication in the US, life-
time prevalence of severe anxiety disorders and
mood disorders were 8.3% and 11.2%, respec-
tively, among 13- to 18-year-old respondents (32).
A previous questionnaire-based study of depressive
disorders in two counties in Norway found that
2.6% of adolescents reported symptoms that ful-
ﬁlled diagnostic criteria for a current major depres-
sive disorder and 23% met criteria for lifetime
depression (33). Despite an observed increase in
AD use, our study shows that <1% of 13- to 17-
year-old girls and boys in Norway had an AD dis-
pensed in 2013. Thus, only a small proportion of
those assumed to have a disorder with a possible
indication for use seems to receive AD drug treat-
ment.
More than four of ﬁve new AD users in our
study had been referred by their GP to specialist
mental healthcare service and were recorded with a
diagnosis of mental or behavioural disorders. This
supports the assumption that those who are most
severely burdened are the ones treated with ADs.
In accordance with this, we found that a third of
the incident AD users had also been prescribed a
hypnotic drug, 13% had been prescribed an
antipsychotic, 6% an anxiolytic drug, and 9% a
stimulant, a marker of psychiatric comorbidity.
Unpublished data from the NPR shows that there
has also been an increase in 1-year prevalence of
diagnosed depressive disorders among 14- to 18-
year olds in the period 2008–2013: from 6.2/1000
to 7.1/1000 of all boys and from 16.5/1000 to 23.0/
1000 of all girls (L. J. Hauge, personal communica-
tion). Thus, one explanation to the increase in
observed AD drug use may be that more adoles-
cents are being referred to specialist mental health
care. In parallel, the proportion of adolescents
Table 2. Antidepressant (AD) of choice among 13- to 17-year-old incident* users in
2012 in Norway
Substances (ATC code) First prescription, n (%)
SSRI
Fluoxetine (N06AB03) 551 (33.1)
Sertraline (N06AB06) 458 (27.5)
Escitalopram (N06AB10) 266 (16.0)
Citalopram (N06AB04) 21 (1.3)
Paroxetine (N06AB05) 10 (0.6)
TCA
Amitriptyline (N06AA09) 145 (8.7)
Trimipramine (N06AA06) 27 (1.6)
Clomipramine (N06AA04) 6 (0.4)
Nortriptyline (N06AA10) 5 (0.3)
Doxepin (N06AA12) 1 (0.1)
MAO-I
Moclobemide (N06AG02) 1 (0.1)
Other substances
Mianserin (N06AX03) 76 (4.6)
Mirtazapine (N06AX11) 69 (4.1)
Venlafaxine (N06AX16) 15 (0.9)
Bupropion (N06AX12) 9 (0.5)
Oxitriptan (N06AX01) 3 (0.2)
Reboxetine (N06AX18) 2 (0.1)
Total 1665 (100)
SSRI, selective serotonin reuptake inhibitor; MAO-I, monoamine oxidase inhibitor;
TCA, tricyclic antidepressant.
Only the first ADs dispensed in 2012 are included in the table.
*Incident use defined as: no ADs dispensed during the 3-year period before the first
dispensing in the actual year.
Table 3. Use of other psychotropic drugs among 13- to 17-year-old incident* antide-
pressant (AD) users in Norway in 2012 (n = 1665)
Type of psychotropic drug† Users in 2012, n (%)
Antipsychotics (N05A) 219 (13.2)
Anxiolytics (N05B) 103 (6.2)
Hypnotics/sedatives‡ 563 (33.8)
Benzodiazepines (N05CD) 7 (0.4)
z-Hypnotics (N05CF) 98 (5.9)
Melatonin agonists (N05CH) 410 (24.6)
Alimemazine (R06AD01) 194 (11.7)
Stimulants (N06BA) 146 (8.8)
*Incident use: no ADs dispensed during the 3-year period before the first dispensing
in the actual year.
†One psychotropic drug dispensed at least once in 2012.
‡Sum of all hypnotics/sedatives >33.8% because of retrieval of more than one
group of hypnotic/sedative by same individual.
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reporting to seek help for mental health problems
has increased (30).
There are only minor gender diﬀerences in psy-
chiatric symptoms among preschool children (34).
Between 6 and 12 years, two of three children with
a diagnosed psychiatric symptoms are boys (35).
While the girl : boy ratio increases for symptoms
of depression and OCD postpuberty (35). This is
reﬂected in our results which show increasing gen-
der diﬀerences in AD use during adolescence, with
an overall girl : boy ratio of about one among 13-
year olds, increasing to almost three in 17-year
olds. Similar gender diﬀerences have also been
documented in prescription data from Denmark
(16).
The type of AD substances used by the adoles-
cents in this study did correspond with the recom-
mendations for AD drug treatment in 9 of 10 new
AD users. When drug treatment of depression,
OCD, and anxiety is indicated, SSRIs should be
considered as ﬁrst-line treatment (8, 10–12). In the
present study, SSRIs were started in almost 80%
of all new users. Fluoxetine and sertraline, which
are approved and recommended as ﬁrst choice in
depression and OCD, were the ﬁrst-line choice in
33% and 27%, respectively, of the new users in
2012. Guidelines also suggest that sertraline may
be prescribed for severe anxiety disorders in chil-
dren, which may contribute to its high prevalence
of use. If treatment fails, guidelines recommend a
switch to another type of SSRI as the ﬁrst step,
and if there is still no response, switch to another
class of AD (e.g. venlafaxine) (8, 10–12). Certain
symptoms or patterns of comorbidity with the
depressive illness may guide the choice of another
AD. If there is need for quick response, for exam-
ple, because of frequent suicidal ideations, citalo-
pram or escitalopram may be the best choice (10).
There have, however, been warnings on an
increased risk for QT interval prolongation on an
ECG with citalopram (36, 37) which may explain
the preference for escitalopram observed in the
present study. Hence, escitalopram and citalopram
were started in 16% and 1% of all new AD users
respectively. The SSRI paroxetine was initiated in
<1% of new AD users, in agreement with speciﬁc
warnings directed at this agent and limited evi-
dence supporting its eﬃcacy (38). For severe sleep-
ing diﬃculties, mirtazapine or mianserin may be
tried (10), tentatively, together with other AD
treatment. In our study, these substances were
started in almost 10% of all new users. Thus, up to
90% of substances of choice in new AD users seem
to agree with the recommendations in the guideli-
nes (10, 38). The remaining 10% of ﬁrst-choice AD
substances were TCAs. In parallel, 5–23% of all
0- to 19-year-old AD users were prescribed TCAs
in a recent study from ﬁve western countries, with
variations between the countries (18). According
to a recent systematic review from the Cochrane
Collaboration, TCAs are of no use in treating
depression in young children. There is, however,
some evidence to support the use of TCAs in the
treatment of severe treatment-resistant depression
in adolescents (13–20 years) (39). The percentage
using the TCA amitriptyline (8.7%) in the present
study may seem high. The drug is also indicated
for the use for chronic pain and enuresis nocturna,
which also might contribute some to the high per-
centage.
Strengths and limitations
The NorPD provides age- and gender-speciﬁc
information on all dispensed ADs prescribed by
all practising physicians and covers the whole
population of adolescents living in Norway. This
approach eliminates the possibility of selection
and recall bias, which may be a problem with
estimates based on prescribing in general practice
only or among selected parts of the population,
or on surveys with self-reported drug use. How-
ever, there are also some limitations. A major
limitation with this study is that beyond the
extent to which new AD users have been referred
to and diagnosed by the specialist mental health
care, no information was available to further
assess and conclude on the appropriateness of
AD use. Important information in this context
would be information on the severity of disease,
the extent to which AD drugs are given in com-
bination with non-pharmacological treatment
options, and follow-up, which is emphasized by
guidelines and thus important in order to assess
the appropriateness of drug-therapy.
Further, we do not know whether the dispensed
drugs reﬂect actual drug use and we have no infor-
mation about drugs administered to hospitalized
adolescents. However, in Norway, very few adoles-
cents are in institutions for long periods, and we
do not expect this lack of information to substan-
tially inﬂuence the estimates of prevalence and
incidence.
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